



INVESTMENT OPPORTUNITY

€480,000 round closing December 2025. (Certified Innovative Enterprise)
50% already secured. Seeking a lead investor to drive major impact.

OUR VISION

Making preventive healthcare accessible, pain-free, radiation-free, accurate, easy and affordable to everyone, everywhere, starting with breast examinations at home.



PROBLEM/ OPPORTUNITY

- **1 in 8 women** over 45 receives a false-negative mammogram
 - **1 in 10 breast cancer cases** occurs before 45
- Only alternative? Breast self-exams, but they are NOT accurate.



SOLUTION/ PRODUCT

We developed a secure platform that uses off-the-shelf affordable thermal cameras, your smartphone and advanced AI to screen for breast cancer at home, targeting 95%+ sensitivity and 90%+ specificity.



BUSINESS MODEL



Freemium: Supports period tracking and breast self-exams guidance.



Premium:
Upgrades to accurate thermal camera exams: €200 upfront, then €30/year for 1 user, €50/year for 2 users, €70/year for 3 users.



MARKET

U.S. and EU women aged 25–64 with smartphones who perform self-breast exams. The market size, estimated using a bottom-up market sizing approach, is: **€530B** (TAM), **€220B** (SAM), and **€1.05B** (SOM).

COMPETITION

Main competitor, **Braster-Pro**, is bulky and expensive. **MammoCheck** aims to replace breast self-exams, with a method 4× more accurate. Indirect competitors include mammography, ultrasound, and MRI-accurate but costly, sometimes painful, involve radiation, require professionals, and aren't suitable for frequent or at-home use.

TEAM

12 members: business professionals, AI engineers, regulatory experts, and doctors experienced in medical device development.

COMPETITIVE ADVANTAGE

The only solution that is affordable, portable, easy to use, pain-free, radiation-free, hardware-agnostic, and requires no training or professionals. Proprietary dataset of 65,000+ breast thermal images for training AI models.

GO TO MARKET STRATEGY

Capital-efficient, partnership-driven B2B2C model with thermal camera suppliers, combining revenue sharing and SaaS. Device offered free to women as a corporate employee benefit, launching in the U.S. post-FDA 510(k) clearance by mid-2026.

TRACTION

Obtained bioethics approval and developed MVP. Spin-out from Frederick University (full IP ownership). Participated in 4 accelerators (EU & U.S.) and 3 startup programs. Winner of 3 national/international competitions.

	2025	2026	2027	2028	2029
REVENUES	0	0	0.01	4.5	34.7
EXPENSES	0.1	0.7	1.2	1.8	4.4
EBITDA	(0.1)	(0.7)	(0.1)	0.3	12.4

CONTACT US

www.mammocheck.co
contact@mammocheck.co

Phone number: +357 96564095